We are advising Laekna Therapeutics in connection with its Series D financing

Davis Polk is advising Laekna Therapeutics in connection with its $61 million Series D financing led by CS Capital with support from Worldstar, and Infinity Capital. Yanchuang Capital as the existing investor continued to support Laekna Therapeutics with additional funding.

Laekna Therapeutics is a clinical-stage global biotechnology company dedicated to developing next generation medicines to treat cancer and liver diseases.

The Davis Polk corporate team includes partners Yang Chu and Xuelin (Steve) Wang, associates and registered foreign lawyers Michael Zhuoran Xu and Iris Li. Members of the Davis Polk team are based in the Hong Kong office.

Copy link to share post